New AI platform helps tribes find funding sources, apply for needed grants, loans
Bazile Panek knows he helped do some good when he sees a tribal representative's sigh of relief after using a new software platform that employs artificial intelligence to find funding opportunities.
'This is going to do great things for Indian Country,' he said.
Panek is the tribal liaison for the company behind the startup AI platform called Syncurrent.
A member of the Red Cliff Band of Lake Superior Ojibwe, Panek saw firsthand the need for services and investment on the reservation in far northern Wisconsin where he was born and raised.
Syncurrent uses AI to quickly gather data from hundreds, even thousands, of websites to find the exact grant, loan or other funding opportunity from federal, state and philanthropic sources that is needed for particular projects and provides information about what's needed to apply.
More artificial intelligence: Want more out of AI? Here are 10 savvy prompts to try out
What used to take hours or days by hand now can take minutes with Syncurrent.
'I hear from so many people who spend more time trying to find grants than actually doing their jobs,' Panek said.
Syncurrent was recently tested by officials for the White Earth Ojibwe Nation in Minnesota.
'The platform's simplicity has allowed us to identify and collaborate on critical funding to meet our community's needs,' said Eugene Sommers, an official for the tribe.
More than a trillion dollars in funding opportunities are available to tribal, local and state governments every year from the federal government, but navigating the process to apply for the funds can be overwhelmingly complex, especially for small staffs.
Syncurrent is the brainchild of technology expert Dhruv Patel and Matthew Jaquez.
The platform's basic plan is free for governments to use; its premium plan is $49 per month per department.
Panek is a longtime colleague of Patel and had urged him to consider the needs of tribal nations early in the development of Syncurrent.
The company recently announced a partnership with the U.S. Department of Interior and the nonprofit Native CDFI Network to make Syncurrent premium free for all tribal nations for 10 years.
'Supporting Tribal Nations is and always will be a main priority for Syncurrent,' said Patel in a statement. 'Through our efforts, we're taking a group of people that have always been pushed to the back of the line and moving them all the way to the front.'
In 2024, Congress approved $32.6 billion in funding to benefit tribal communities, but much of that money may not be reaching them, according to the U.S. Government Accountability Office.
For example, the USDA invested about $6.6 billion to support rural development between 2017 and 2021, but only about $138 million went to tribal communities.
The government department's report blames the red tape and paperwork in finding and applying for funding as a major part of the problem.
'Tribal Nations have long faced systemic barriers to accessing capital and securing their fair share of federal, state, and philanthropic dollars,' said Pete Upton, CEO of Native CDFI Network, in a statement. "Syncurrent's AI technology will enable tribal governments to identify and secure critical funding much more quickly, efficiently, and effectively, empowering them to build stronger, healthier, and more prosperous communities."
Syncurrent can currently be accessed for free by tribal governments through its website, Syncurrent.com.
Frank Vaisvilas is a former Report for America corps member who covers Native American issues in Wisconsin based at the Milwaukee Journal Sentinel. Contact him at fvaisvilas@gannett.com or 815-260-2262. Follow him on Twitter at @vaisvilas_frank.
This article originally appeared on Milwaukee Journal Sentinel: New AI platform helps tribes find funding and apply for federal grants
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Medical equipment repair is a fast-growing healthcare career. The average salary is $65,000, and it doesn't require a 4-year degree.
Healthcare technology management, or HTM, is a growing field with promising career opportunities — but it's one that remains under the radar. It ranked 22nd in the US News & World Report's list of the 100 best jobs of 2025. And according to a report from the US Bureau of Labor Statistics, jobs in medical equipment repair are expected to grow by 18% between 2023 and 2033 — a faster rate than average for all occupations. Several factors are driving this growth. Medical equipment repairers or biomedical equipment technicians are an increasingly vital part of the healthcare ecosystem. They maintain, calibrate, and repair everything from vital-sign monitors to MRIs. "You can't deliver healthcare without either a patient, a provider, or an instrument," Jinesh Patel, the founder and CEO of the medical equipment management company UptimeHealth, told Business Insider. "Without an X-ray, the radiologist isn't doing anything. Without a vitals monitor, the nurse can't tell you what's going on." The industry is also aging out faster than new BMETs can be trained. A survey from the Association for the Advancement of Medical Instrumentation found that about a third of HTM professionals are over 55. "A large portion of our experienced workforce is reaching retirement age, leaving a significant talent gap across the country," said Kristi McDermott, the chief operating officer of the clinical asset management company Trimedx. She added that too few people know about the viability, or even existence, of this profession. "There's going to be a vacuum of knowledge very soon," said Patel, who added that he regularly struggles to find enough technicians for his hiring needs. The US Bureau of Labor Statistics projects 7,300 openings for medical equipment repairers each year over the next decade; meanwhile, the Association for the Advancement of Medical Instrumentation reports that BMET programs only graduate about 400 students a year. "This is a huge labor demand that isn't being met, and this is the time, in my opinion, for anyone to get involved," Patel told BI. BMET careers are accessible, well-paid, and meaningful While many other high-growth healthcare jobs require advanced degrees, medical equipment repair is a career you can start more quickly and affordably. Many technicians enter the field with just an associate degree, meaning they have relatively minimal college debt, and earn an average entry-level salary of about $65,000 a year. "That's a high ROI on day one," Richard Gonzales, the president of the College of Biomedical Equipment Technology, said. Some jobs require even less prior education and training, as some employers offer paid apprenticeships or on-the-job training to meet skyrocketing demand. Gonzales said that his college is constantly working with top-tier healthcare organizations to help technicians land jobs faster. "These organizations all want the same thing — to reduce the time it takes to establish minimum competency for an entry-level technician — and they're willing to put in the sweat equity to support that individual's career path," he explained. Many BMETs are also inspired by the ability to have a real-world impact on people's lives. "You are actually helping create access to healthcare. Every time you get a machine back up and running, a patient can be seen on that machine again," Patel said. "If you're interested in pursuing a career that has real meaning, just look at the patient connected to the device — you're making a difference," Gonzales said. He added that he sees a lot of veterans, like himself, pursue this as a second career for just that reason: "You served your country, now you can serve your community." A future-proof trade for a modern healthcare system Patel likened medical equipment repair to trade careers like plumbing and electrician work: The need for those jobs isn't going away anytime soon. "There's no world, at least that we can perceive, that equipment will not be used to help facilitate healthcare," he said. "It's almost a guaranteed profession." Gonzales said the opportunities for career growth are broad for technicians who are excited to continue learning. "When you think about innovation, medical device integration, cybersecurity, network medical devices, advances in patient care, and AI," he said, "somebody is either designing and creating these devices, installing them, hooking them to patients, or maintaining and repairing them." Patel added that the industry is ripe for new people to come in and help shape its future: "If people get excited about not just doing a job, but being the next wave of leaders and people who help take it to the next level, this is the place to do it."
Business Wire
a day ago
- Business Wire
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on ' Beyond Bispecifics and ADCs: Conditionally Active Biologics.' Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs. The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky.
Yahoo
a day ago
- Yahoo
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
